You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Modern Radiotherapy (RT) plays a key role in the management of Head and Neck Cancer (HNC). More precise delivery techniques, advanced image-guidance, and adaptive treatments characterize modern RT, enabling safer treatments with enhanced therapeutic window. Although patients identify the cure as their most important treatment outcome, complications related to treatment are a recognized problem as follow-up increases among those cured within this oncologic setting. This is particularly relevant for HPV-related oropharyngeal cancer (OPSCC), as these patients are younger, healthier, and more reactive to treatment. Thus, given the longer life expectancy, the jeopardizing impact of side effects on quality of life (QoL) and psychosocial functioning represent a forefront topic for HNC Researchers. De-escalation protocols have been developed recently, and, although not definitive, evidence is growing. This pertains particularly, but not exclusively, to HPV-related OPSCC.
This open access book discusses the most current issues in head and neck cancer with a focus on current trends such as biomarkers, precision medicine and immunotherapy. New approaches in the diagnosis such as liquid biopsies and imaging biomarkers to predict radiotherapy toxicity as well as approaches in the surgical management of head and neck cancers are discussed. The book discusses medical and surgical approaches in both primary, recurrent and metastatic disease and also covers approaches for rare head neck cancers. Readers will learn about the latest drug developments and epidemiological aspects in cancers ranging from Head and Neck Squamous Cell Cancer to Nasopharynx cancer. Edited by a team of world leaders in Head and Neck Cancer, this volume serves as an easy reference to the head and neck oncology practitioner and provides a contemporary overview for specialists the field. The chapters are based on the latest data presented at the 7th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.
Salivary gland carcinomas (SGCs) are a heterogeneous group of rare head and neck cancers made of more than 20 pathologic types. Although the treatments of the early or loco-regionally advanced disease are similar across the different entities, these malignancies have variable biological characteristics and clinical behaviors. These specificities, especially the pathologic type and, when available, the molecular profile, are taken into account while choosing the treatment for the recurrent/metastatic phase. In this context, only few druggable molecular targets have been tested so far and not all are available in clinical practice. However, due to the rarity of SGCs, clinical trials are challenging to conduct, and most of the available evidence comes from retrospective studies.
None